Ana Luisa Perdigoto, MD, PhD
Assistant Professor of Medicine (Endocrinology)Cards
About
Research
Publications
2026
Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations
Herold K, Perdigoto A. Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations. Journal Of Clinical Investigation 2026, 136: e202477. PMID: 41697752, PMCID: PMC12904721, DOI: 10.1172/jci202477.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLife-threatening complicationsAutoimmune diabetesLife-threatening complications of immune checkpoint inhibitorsComplication of immune checkpoint inhibitorsImmune checkpoint inhibitor treatmentICI-treated patientsImmune cell activationCheckpoint inhibitorsPancreatic volumeIslet autoantibodiesCell activationTreatment decisionsMatched ControlsRisk factorsClinical implicationsPrevention strategiesPatientsTreatmentDiabetesLife-alteringCheckpointAutoantibodiesComplicationsPBMCAnti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes
Wu Y, Spurrell M, Lledó-Delgado A, Deng S, Wang D, Liu Y, Barkestani M, Perdigoto A, Herold K. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes. JCI Insight 2026, 11: e192755. PMID: 41574610, PMCID: PMC12892913, DOI: 10.1172/jci.insight.192755.Peer-Reviewed Original ResearchConceptsAnti-CD3 mAb treatmentT cellsMAb treatmentAutoimmune diabetesB cellsCD8+ T cellsIslet-infiltrating T cellsAnti-CD3 monoclonal antibodyT-cell receptor sequencingPrediabetic NOD miceAutoreactive T cellsPancreatic lymph nodesImmune-mediated destructionCourse of treatmentType 1 diabetesInfiltrating TSingle-cell RNAIslet infiltrationMAb-treatedNOD miceLymph nodesEffector functionsOperational toleranceMonoclonal antibodiesProlonged effect
2025
Towards insulin independence in type 1 diabetes: Prospects for prevention and cure
Sydney G, Perdigoto A, Herold K. Towards insulin independence in type 1 diabetes: Prospects for prevention and cure. PLOS Medicine 2025, 22: e1004813. PMID: 41289263, PMCID: PMC12646415, DOI: 10.1371/journal.pmed.1004813.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients
Gaiger N, Hurwitz M, Hafez N, Kluger H, Herold K, Perdigoto A. Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients. Frontiers In Endocrinology 2025, 16: 1697724. PMID: 41282287, PMCID: PMC12634352, DOI: 10.3389/fendo.2025.1697724.Peer-Reviewed Original ResearchConceptsLife-threatening complicationsTNF-aImmune-related adverse eventsImmune checkpoint inhibitor therapyDestruction of pancreatic beta cellsSpontaneous autoimmune diabetesCheckpoint inhibitor therapyTreated with infliximabC-peptide levelsBeta-cell destructionBeta-cell functionInfliximab treatmentInhibitor therapyAdvanced malignanciesPancreatic beta cellsAutoimmune diabetesIrreversible complicationsClinical outcomesCase reportAdverse eventsInfliximabInflammatory cytokinesLabile diabetesInsulin treatmentDiabetic controlConsensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Zhu L, Cheung Y, Chiang C, Gallagher E, Hamnvik O, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Warner A, Blackwell S, Calabrese C, Cho T, Dougan M, Ferreira M, Funchain P, Herndon J, Johnson D, Kennedy R, Kheterpal M, Khouri M, Lechner M, Lim A, Markova A, Meara A, Overton L, Perdigoto A, Sachithanandan N, Sharon E, Spain L, Tsai K, Yarchoan M, Reynolds K, Shariff A. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2025, 13: e011865. PMID: 41093625, PMCID: PMC12530408, DOI: 10.1136/jitc-2025-011865.Peer-Reviewed Original ResearchConceptsEndocrine immune-related adverse eventsImmune checkpoint inhibitorsICI-treated patientsCheckpoint inhibitorsImmune-related adverse events of immune checkpoint inhibitorsAdverse events of immune checkpoint inhibitorsRAND/University of California Los AngelesImmune-related adverse eventsDisease definitionAssessment of severityGroup of endocrinologistsThyrotoxic phaseTime-sensitive managementRadiological evaluationConsensus-based statementsAdverse eventsDiabetes mellitusSymptom evaluationWork-upVoting panelCancer treatmentCare escalationDiseaseMellitusEndocrinologistsCTLA-4 blockade shifts the B cell repertoire towards autoimmunity
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas C, Bouis D, Boeckers J, Gera R, Yraita S, Clapp L, Perdigoto A, Delmotte F, Massad C, Bacchiocchi A, Ring A, Kluger Y, Kluger H, Herold K, Meffre E. CTLA-4 blockade shifts the B cell repertoire towards autoimmunity. Journal Of Clinical Investigation 2025, 135: e189074. PMID: 41026527, PMCID: PMC12618075, DOI: 10.1172/jci189074.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAnti-PD-1CTLA-4 blockadeMature naive B cellsCTLA-4Naive B cellsB cell repertoireB cellsCheckpoint inhibitorsPD-1Emergence of immune-related adverse eventsAnti-CTLA-4 combination therapyCancer patientsReactivity of recombinant antibodiesCentral B cell tolerancePeripheral B cell repertoireAnti-CTLA-4B cell frequenciesBlood of cancer patientsAutoreactive B cellsB cell toleranceTreatment of cancer patientsSingle B cellsAntitumor responseCombination therapyFactors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Aizenbud L, Gaiger N, Perdigoto A, Mann J, Torres M, Boland G, Lawless A, Silverman S, Schoenfeld D, Destina J, Hasson N, Tran T, Hurwitz M, Austin M, Sullivan R, Herold K, Kluger H. Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. Journal For ImmunoTherapy Of Cancer 2025, 13: e012358. PMID: 40935567, DOI: 10.1136/jitc-2025-012358.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsICI-induced colitisICI-induced hypophysitisHLA-GNon-overlapping cohortsInterferon-gRisk of immune-related adverse eventsExpression of class I major histocompatibility complexClass I MHC expressionGeneral populationICI-treated patientsPeripheral blood mononuclear cellsMissense variantsInsulin-dependent diabetes mellitusSurvival of patientsCohort of patientsBlood mononuclear cellsClass I major histocompatibility complexGermline missense variantsClass I MHC moleculesMessenger RNA expressionCheckpoint inhibitorsThyroid patientsAdverse eventsAutoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas
Quandt Z, Young A, Barlow G, Smith J, Kusmartseva I, Dong S, Shapiro M, Kang J, Felton J, Nguyen V, Szot G, Hassoun A, Perdigoto A, Herold K, Nolan G, Bollyky P, Brusko T, Nakayama M, Cooper S, Anderson M. Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal For ImmunoTherapy Of Cancer 2025, 13: e011818. PMID: 40813111, PMCID: PMC12359507, DOI: 10.1136/jitc-2025-011818.Peer-Reviewed Original ResearchConceptsProgrammed death 1 (PD-1)/programmed death ligand 1Immune-related adverse eventsDeep immune phenotypingDeath-ligand 1Pancreatic cancer treatmentHistory of diabetesSurgically resected pancreasMetastatic melanomaAutoimmune originLymphocytic infiltrationImmune phenotypePancreatic cancerAdverse eventsAutoimmune diseasesInsulin therapySingle-cell RNA sequencingUnique patientsPancreatic tissueCancer treatmentMonoclonal antibodiesPatientsPancreasTreatmentRNA sequencingImmunophenotype
2024
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.
Quandt Z, Perdigoto A, Anderson M, Herold K. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives In Medicine 2024, 15: a041603. PMID: 39038853, PMCID: PMC11917379, DOI: 10.1101/cshperspect.a041603.Peer-Reviewed Original ResearchAutoimmune diabetesBlockade of programmed cell death protein 1Agents targeting immune checkpointsCell death protein 1Autoimmune side effectsPD-L1Immune checkpointsAutoimmune disease riskClinical findingsAdverse eventsLevels of lipaseSide effectsInflammatory processIslets of LangerhansProtein 1DiabetesDisease riskIncreased levelsCheckpointAutoantibodiesBlockadeCancerPancreasDiagnosisLangerhansThe immunology of type 1 diabetes
Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.Peer-Reviewed Original ResearchType 1 diabetesT cellsDestruction of pancreatic B-cellsImmune-targeted interventionsTarget T cellsPathogenesis of T1DB-cell massPancreatic B-cellsAutoimmune destructionB cellsGlucose dysregulationImmune mechanismsImmune systemNatural historyDisease pathogenesisT1DRegulatory approvalTreatment of individualsDiscovery of insulinPathogenesisDiseaseSeminal discoveriesImmunotherapy
Academic Achievements & Community Involvement
News
News
- July 01, 2025
How Immune Checkpoint Inhibitors Can Induce Diabetes
- January 06, 2025
Request for Nominations: 2025 Iva Dostanic Award
- August 01, 2024
Meet Yale Internal Medicine: Ana Luisa Perdigoto, MD, PhD
- June 05, 2023
Discoveries & Impact (June 2023)
Get In Touch
Contacts
Events
May 20261Friday
Everyone
May 202629Friday
Everyone Ryan MacLeod, MD, PhD